Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome®): A 91-day study in rats

Pharmaceutical Research

Volumn 17, Issue 12, 2000, Pages 1494-1502

  Bekersky, I ^a   Boswell, G W ^b   Hiles, R ^c   Fielding, R M ^d   Buell, D ^a   Walsh, T J ^e  

^a ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^b Calvert Preclinical Services   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d Biologistic Services Boulder   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Amphotericin B; Liposomes; Pharmacokinetics; Tissue distribution; Toxicity; Toxicokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; AUTOPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; FEMALE; HISTOPATHOLOGY; LIVER TOXICITY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; TOXICOKINETICS;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; AREA UNDER CURVE; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; BLOOD UREA NITROGEN; DELAYED-ACTION PREPARATIONS; FEMALE; HALF-LIFE; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 0034469250     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007605024942     Document Type: Article

References (30)

1. Lipid-based amphotericin B formulations: From animals to man
2. Relationship of pharmacokinetics and tissue distribution to reduced toxicity of colloidal amphotericin B in dogs
3. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: Single-dose studies
4. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections
5. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: A preliminary study
6. Amphotericin B lipid complex
7. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents
8. Therapeutic efficacy of a liposomal formulation of amphotericin B (AmBisome) against murine blastomycosis
9. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients
10. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
11. A randomized double-blind safety study of AmBisome and Abelcet in febrile neutropenic patients
12. New approaches to systemic antifungal therapy: Case studies of AmBisome and FK 463
13. Liposomal amphotericin B: Therapeutic use in the management of fungal infections and visceral leishmaniasis
14. AmBisome (liposomal amphotericin B): A comparative review
15. High-dose liposomal amphotericin B in patients infected with aspergillosis and other filamentous fungi
16. Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats
17. Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome) in Beagle dogs
18. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome®)
19. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation
20. Hypercholesterolemic effect of amphotericin B: An analytical approach
21. Non-clinical studies of the efficacy, pharmacokinetics and safety of amphotericin B colloidal dispersion (ABCD)
22. Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats
23. Comparative intravenous toxicity of cisplatin solution and cisplatin encapsulated in longcirculating, pegytated liposomes in cynomolgus monkeys
24. Clinical and preclinical studies with low-clearance liposomal Amikacin (Mi-Kasome)
25. Chronic amphotericin B nephrotoxocity in the rat: Protective effect of calcium channel blockade
26. Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil) and Fungizone after repeated dosing in rats
27. Disposition kinetics of amphotericin B in rats, the influence of dose
28. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats
29. Reversible depression of the reticuloendothelial system by liposomes
30. Liposomal targeting and drug delivery: Kinetic consideration